Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2016
"Human
Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2
2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Human Immunodeficiency Virus Infections (AIDS)
Pipeline Review, H2 2016, provides an overview of the Human
Immunodeficiency Virus Infections (AIDS) (Infectious Disease)
pipeline landscape.
HIV
is a virus which attacks the immune system, and weakens ability to
fight infections and disease. Symptoms include fever, sore throat,
body rash, joint pain, muscle pain and swollen glands. The most
common ways HIV is spread are by having vaginal or anal intercourse
without a condom with someone who has HIV/AIDS, sharing needles or
syringes with someone who has HIV/AIDS, being deeply punctured with a
needle or surgical instrument contaminated with HIV and getting
HIV-infected blood, semen, or vaginal secretions into open wounds or
sores.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus Infections (AIDS) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 17, 43, 45, 2, 108, 75 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 15, 15, 51 and 67 molecules, respectively.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus Infections (AIDS) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 17, 43, 45, 2, 108, 75 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 15, 15, 51 and 67 molecules, respectively.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Human Immunodeficiency Virus Infections (AIDS)
(Infectious Disease).
-
The pipeline guide reviews pipeline therapeutics for Human
Immunodeficiency Virus Infections (AIDS) (Infectious Disease) by
companies and universities/research institutes based on information
derived from company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Human
Immunodeficiency Virus Infections (AIDS) (Infectious Disease)
therapeutics and enlists all their major and minor projects.
-
The pipeline guide evaluates Human Immunodeficiency Virus Infections
(AIDS) (Infectious Disease) therapeutics based on mechanism of action
(MoA), drug target, route of administration (RoA) and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Human Immunodeficiency Virus Infections (AIDS)
(Infectious Disease)
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Human Immunodeficiency Virus Infections (AIDS)
(Infectious Disease).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease)
pipeline depth and focus of Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Comments
Post a Comment